Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma: Case Report

V. Walavalkar, D. B. Adey, Z. G. Laszik, Kuang-Yu Jen

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Lenalidomide, a thalidomide analogue, is an immunomodulatory drug currently used as a chemotherapeutic agent in treating certain hematologic malignancies, including multiple myeloma. The antineoplastic effect of lenalidomide may be due to its ability to modulate different components of the immune system as well as its antiangiogenic, antiproliferative, and direct cytotoxic activity. Given its immunomodulatory effects, lenalidomide may potentially elicit unintended immune activity against allografts in solid organ transplant recipients. Here, we present a case of a renal transplant recipient who developed multiple myeloma after transplantation and was treated with the use of lenalidomide, which precipitated severe acute T-cell–mediated rejection. Lenalidomide was thought to be causative, and after cessation of the drug her renal function stabilized.

Original languageEnglish (US)
Pages (from-to)873-876
Number of pages4
JournalTransplantation Proceedings
Volume50
Issue number3
DOIs
StatePublished - Apr 1 2018

Fingerprint

Multiple Myeloma
Allografts
Kidney
Therapeutics
Thalidomide
Hematologic Neoplasms
Pharmaceutical Preparations
Antineoplastic Agents
Immune System
Transplantation
lenalidomide
Transplants
Transplant Recipients

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma : Case Report. / Walavalkar, V.; Adey, D. B.; Laszik, Z. G.; Jen, Kuang-Yu.

In: Transplantation Proceedings, Vol. 50, No. 3, 01.04.2018, p. 873-876.

Research output: Contribution to journalArticle

@article{051ec00247544b4cbf2db5a2b9a56443,
title = "Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma: Case Report",
abstract = "Lenalidomide, a thalidomide analogue, is an immunomodulatory drug currently used as a chemotherapeutic agent in treating certain hematologic malignancies, including multiple myeloma. The antineoplastic effect of lenalidomide may be due to its ability to modulate different components of the immune system as well as its antiangiogenic, antiproliferative, and direct cytotoxic activity. Given its immunomodulatory effects, lenalidomide may potentially elicit unintended immune activity against allografts in solid organ transplant recipients. Here, we present a case of a renal transplant recipient who developed multiple myeloma after transplantation and was treated with the use of lenalidomide, which precipitated severe acute T-cell–mediated rejection. Lenalidomide was thought to be causative, and after cessation of the drug her renal function stabilized.",
author = "V. Walavalkar and Adey, {D. B.} and Laszik, {Z. G.} and Kuang-Yu Jen",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.transproceed.2018.01.014",
language = "English (US)",
volume = "50",
pages = "873--876",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma

T2 - Case Report

AU - Walavalkar, V.

AU - Adey, D. B.

AU - Laszik, Z. G.

AU - Jen, Kuang-Yu

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Lenalidomide, a thalidomide analogue, is an immunomodulatory drug currently used as a chemotherapeutic agent in treating certain hematologic malignancies, including multiple myeloma. The antineoplastic effect of lenalidomide may be due to its ability to modulate different components of the immune system as well as its antiangiogenic, antiproliferative, and direct cytotoxic activity. Given its immunomodulatory effects, lenalidomide may potentially elicit unintended immune activity against allografts in solid organ transplant recipients. Here, we present a case of a renal transplant recipient who developed multiple myeloma after transplantation and was treated with the use of lenalidomide, which precipitated severe acute T-cell–mediated rejection. Lenalidomide was thought to be causative, and after cessation of the drug her renal function stabilized.

AB - Lenalidomide, a thalidomide analogue, is an immunomodulatory drug currently used as a chemotherapeutic agent in treating certain hematologic malignancies, including multiple myeloma. The antineoplastic effect of lenalidomide may be due to its ability to modulate different components of the immune system as well as its antiangiogenic, antiproliferative, and direct cytotoxic activity. Given its immunomodulatory effects, lenalidomide may potentially elicit unintended immune activity against allografts in solid organ transplant recipients. Here, we present a case of a renal transplant recipient who developed multiple myeloma after transplantation and was treated with the use of lenalidomide, which precipitated severe acute T-cell–mediated rejection. Lenalidomide was thought to be causative, and after cessation of the drug her renal function stabilized.

UR - http://www.scopus.com/inward/record.url?scp=85045388373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045388373&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2018.01.014

DO - 10.1016/j.transproceed.2018.01.014

M3 - Article

C2 - 29661456

AN - SCOPUS:85045388373

VL - 50

SP - 873

EP - 876

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 3

ER -